The PEARL II study is a double-blind, non- inferiority trial in 307 patients with fibroids and excessive uterine bleeding (PBAC >100) receiving 3 months daily 5 mg UPA (n=98), 10 mg UPA (n=104) or monthly injection of Leuprolide, a GnRH-analogue. Here, GNRH1 is linked to leiomyoma.